305 related articles for article (PubMed ID: 26600226)
1. Treatment of Chronic Hepatitis C in Special Populations.
Bunchorntavakul C; Tanwandee T
Gastroenterol Clin North Am; 2015 Dec; 44(4):883-900. PubMed ID: 26600226
[TBL] [Abstract][Full Text] [Related]
2. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective.
Hawkins C; Grant J; Ammerman LR; Palella F; Mclaughlin M; Green R; Mcgregor D; Stosor V
J Antimicrob Chemother; 2016 Sep; 71(9):2642-5. PubMed ID: 27330060
[TBL] [Abstract][Full Text] [Related]
3. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
[TBL] [Abstract][Full Text] [Related]
4. Interferon-free regimens for the treatment of hepatitis C virus in liver transplant candidates or recipients.
Cholongitas E; Pipili C; Papatheodoridis G
World J Gastroenterol; 2015 Aug; 21(32):9526-33. PubMed ID: 26327760
[TBL] [Abstract][Full Text] [Related]
5. Impact of new treatment options for hepatitis C virus infection in liver transplantation.
Righi E; Londero A; Carnelutti A; Baccarani U; Bassetti M
World J Gastroenterol; 2015 Oct; 21(38):10760-75. PubMed ID: 26478668
[TBL] [Abstract][Full Text] [Related]
6. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
Molina JM; Orkin C; Iser DM; Zamora FX; Nelson M; Stephan C; Massetto B; Gaggar A; Ni L; Svarovskaia E; Brainard D; Subramanian GM; McHutchison JG; Puoti M; Rockstroh JK;
Lancet; 2015 Mar; 385(9973):1098-106. PubMed ID: 25659285
[TBL] [Abstract][Full Text] [Related]
7. Direct acting antiviral therapy after liver transplantation.
Kwo PY
Curr Opin Gastroenterol; 2016 May; 32(3):152-8. PubMed ID: 27023161
[TBL] [Abstract][Full Text] [Related]
8. Key drug-drug interactions with direct-acting antiviral in HIV-HCV coinfection.
El-Sherif O; Khoo S; Solas C
Curr Opin HIV AIDS; 2015 Sep; 10(5):348-54. PubMed ID: 26248122
[TBL] [Abstract][Full Text] [Related]
9. New hepatitis C therapies for special patient populations.
Soriano V; Labarga P; de Mendoza C; Fernández-Montero JV; Esposito I; Benítez-Gutiérrez L; Peña JM; Barreiro P
Expert Opin Pharmacother; 2016; 17(2):217-29. PubMed ID: 26595348
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis.
Merli M; Galli L; Marinaro L; Ariaudo A; Messina E; Uberti-Foppa C; Castagna A; D'Avolio A; Lazzarin A; Bonora S; Hasson H
J Antimicrob Chemother; 2017 Mar; 72(3):812-815. PubMed ID: 27999010
[TBL] [Abstract][Full Text] [Related]
11. High frequency of potential interactions between direct-acting antivirals and concomitant therapy in HIV/hepatitis C virus-coinfected patients in clinical practice.
Macías J; Monge P; Mancebo M; Merchante N; Neukam K; Real LM; Pineda JA
HIV Med; 2017 Aug; 18(7):445-451. PubMed ID: 27882706
[TBL] [Abstract][Full Text] [Related]
12. All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV-coinfected subjects in real-world practice: Madrid coinfection registry findings.
Berenguer J; Gil-Martin Á; Jarrin I; Moreno A; Dominguez L; Montes M; Aldámiz-Echevarría T; Téllez MJ; Santos I; Benitez L; Sanz J; Ryan P; Gaspar G; Alvarez B; Losa JE; Torres-Perea R; Barros C; Martin JVS; Arponen S; de Guzmán MT; Monsalvo R; Vegas A; Garcia-Benayas MT; Serrano R; Gotuzzo L; Menendez MA; Belda LM; Malmierca E; Calvo MJ; Cruz-Martos E; González-García JJ
Hepatology; 2018 Jul; 68(1):32-47. PubMed ID: 29377274
[TBL] [Abstract][Full Text] [Related]
13. New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir.
McConachie SM; Wilhelm SM; Kale-Pradhan PB
Expert Rev Clin Pharmacol; 2016; 9(2):287-302. PubMed ID: 26651915
[TBL] [Abstract][Full Text] [Related]
14. Special populations: treating hepatitis C in patients with decompensated cirrhosis and/or advanced renal impairment.
Mücke MM; Mücke VT; Lange CM; Zeuzem S
Liver Int; 2017 Jan; 37 Suppl 1():19-25. PubMed ID: 28052635
[TBL] [Abstract][Full Text] [Related]
15. New Direct Acting Antiviral Agents for the Treatment of Hepatitis C: 2016 and Beyond.
Umar M; Akhter TS
J Coll Physicians Surg Pak; 2016 Oct; 26(10):843-850. PubMed ID: 27806815
[TBL] [Abstract][Full Text] [Related]
16. Treatment of hepatitis C in difficult-to-treat patients.
Ferenci P
Nat Rev Gastroenterol Hepatol; 2015 May; 12(5):284-92. PubMed ID: 25895822
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Advances in HCV Genotype 1 Infection: Insights from the Society of Infectious Diseases Pharmacists.
Deming P; Martin MT; Chan J; Dilworth TJ; El-Lababidi R; Love BL; Mohammad RA; Nguyen A; Spooner LM; Wortman SB
Pharmacotherapy; 2016 Feb; 36(2):203-17. PubMed ID: 26846728
[TBL] [Abstract][Full Text] [Related]
18. Challenges in Special Populations: HIV/HCV Coinfection, Liver Transplantation and Patients with End-Stage Renal Disease.
Bonacci M; Lens S; Mariño Z; Forns X
Dig Dis; 2016; 34(4):317-26. PubMed ID: 27170384
[TBL] [Abstract][Full Text] [Related]
19. Treatment Considerations for Unique Patient Populations With HCV Genotype 1 Infection.
Toussaint-Miller KA; Andres J
Ann Pharmacother; 2015 Sep; 49(9):1015-30. PubMed ID: 26139639
[TBL] [Abstract][Full Text] [Related]
20. The Drug-Drug Interaction Potential of Antiviral Agents for the Treatment of Chronic Hepatitis C Infection.
Garrison KL; German P; Mogalian E; Mathias A
Drug Metab Dispos; 2018 Aug; 46(8):1212-1225. PubMed ID: 29695614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
